Intravesical Instillation Chemotherapy with Gemcitabine in Preventing Recurrence of Non-muscle Infiltration Bladder Cancer after Transurethral Resection
This paper investigates the efficacy of gemcitabine in the treatment of non-muscle infiltration bladder cancer (NMIBC) after transurethral resection (TURBT) and after recurrence. The observation group was given intraperitoneal injection of gemcitabine, and the control group was given intraperitoneal injection of pirarubicin. The two groups were followed up for 2 years. The recurrence rate of the two groups was observed. The tumor recurrence rate in the observation group was significantly lower than that in the control group within 2 years (X2=5.444, P<0.05), and the recurrence time was significantly longer than that of the control group (t=7.051, P<0.05). The rate of tumor recurrence in the observation group was significantly lower than that in the control group within two years (X2=3.463, P<0.05), and the progression time was significantly higher than that of the control group (t=1.996, P<0.05). There were 10 cases (13.33%) of adverse reactions in the observation group and 23 cases (30.67%) in the control group. The difference between the two groups was statistically significant (X2=6.566, P<0.05). Intravesical instillation chemotherapy with gemcitabine has excellent curative effect on tumor recurrence after TURBI surgery in non-muscle invasive bladder cancer. The incidence of adverse reactions is also very low. It is recommended that the attending doctor should use it reasonably according to the actual situation of the patient.